Xilio Therapeutics (XLO) Return on Capital Employed (2021 - 2026)

Xilio Therapeutics has disclosed Return on Capital Employed across 6 years of filings, most recently posting 36.38% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 36.38%, up 10685.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 36.38% (up 10685.0% YoY), and the FY2025 annual result was 74.16%, up 8222.0% from the prior year.
• Return on Capital Employed came in at 36.38% for Q1 2026 at Xilio Therapeutics, up from 47.75% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 36.38% in Q1 2026 to a low of 181.89% in Q1 2024.
• The 5-year median for Return on Capital Employed is 86.42% (2025), against an average of 96.88%.
• Across the five-year window, Return on Capital Employed slumped 9810 bps in 2024 and surged 10685 bps in 2026, its largest moves.
• Xilio Therapeutics' Return on Capital Employed stood at 70.1% in 2022, then sank by 111 bps to 148.11% in 2023, then climbed by 10 bps to 132.84% in 2024, then soared by 64 bps to 47.75% in 2025, then grew by 24 bps to 36.38% in 2026.
• The last three Return on Capital Employed figures came in at 36.38% (Q1 2026), 47.75% (Q4 2025), and 56.59% (Q3 2025), per Business Quant data.